PharmaShots | Incisive News in 3 Shots

Subscribe Now

Non-Radiographic Axial Spondyloarthritis

AbbVie's Rinvoq (upadacitinib) Met Primary and Secondary Endpoints in P-III SELECT-AXIS 2 Clinical Trial for Non-Radiographic Axial Spondyloarthritis

AbbVie's Rinvoq (upadacitinib) Met Primary and Secondary Endpoints in P-III SELECT-AXIS 2 Clinical Trial for Non-Radiographic Axia...

October 8, 2021

Lilly's Taltz (ixekizumab) Receives Health Canada Approval for Non-Radiographic Axial Spondyloarthritis

Lilly's Taltz (ixekizumab) Receives Health Canada Approval for Non-Radiographic Axial Spondyloarthritis

October 21, 2020

Novartis' Cosentyx (secukinumab) Receives the US FDA's Approval for Active Non-Radiographic Axial Spondyloarthritis

Novartis' Cosentyx (secukinumab) Receives the US FDA's Approval for Active Non-Radiographic Axial Spondyloarthritis

June 17, 2020

UCB's Cimzia (certolizumab pegol) Receives Health Canada Approval for Non-Radiographic Axial Spondyloarthritis

UCB's Cimzia (certolizumab pegol) Receives Health Canada Approval for Non-Radiographic Axial Spondyloarthritis

January 16, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us